1.2K
Articles
23.6K
Citations
3.7
avg. Impact Factor
69
h-index

Most Cited Articles of Department of Medical Oncology in 2021

TitleJournalYearCitations
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant TrialsJournal of Clinical Oncology202127
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinomaAnnals of Oncology202121
Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance databaseEuropean Heart Journal - Cardiovascular Pharmacotherapy202117
Clinical practice guidelines for BRCA1 and BRCA2 genetic testingEuropean Journal of Cancer202115
Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancerEuropean Journal of Cancer202115
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trialLancet Oncology, The202115
Telemedicine in Audiology. Best practice recommendations from the French Society of Audiology (SFA) and the French Society of Otorhinolaryngology-Head and Neck Surgery (SFORL)European Annals of Otorhinolaryngology, Head and Neck Diseases202113
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update ConsortiumJournal of Clinical Oncology202113
Specific Genomic Alterations in High-Grade Pulmonary Neuroendocrine Tumours with Carcinoid MorphologyNeuroendocrinology202113
Management of Adults and Children receiving CAR T-cell therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).Annals of Oncology202112
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphomaBritish Journal of Haematology202112
Five-Year Survival Outcomes of Hybrid Minimally Invasive Esophagectomy in Esophageal Cancer: Results of the MIRO Randomized Clinical TrialJAMA Surgery202111
Assessing the impact of COVID-19 on liver cancer management (CERO-19)JHEP Reports202111
Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Analysis of the PRODIGE-GERCOR IDEA-France TrialClinical Cancer Research202111
Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch RepairGastroenterology202111
Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature reviewEuropean Journal of Cancer202110
Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISATalanta202110
Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic ReviewEuropean Urology202110
Comprehensive integrative profiling of upper tract urothelial carcinomasGenome Biology202110
The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib ProgramTargeted Oncology20219
Inherited GATA2 Deficiency Is Dominant by Haploinsufficiency and Displays Incomplete Clinical PenetranceJournal of Clinical Immunology20219
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 TrialJournal of Clinical Oncology20219
Clinicopathologic Features and Response to Therapy of Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter RegistryJournal of Clinical Oncology20219
Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancerESMO Open20218
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphomaBritish Journal of Haematology20218